Clinical trials: Resolution
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Infection, Wound Healing Problem
Fluid Lavage of Open Wounds (FLOW): Pilot Trial
The purpose of this trial is to investigate whether irrigation solution (soap vs. saline solution), or irrigation pressure (high vs. low) will decrease the rate of infection among patients with open fracture wounds.
- Conditions
- Infection, Wound Healing Problem, Nonunion
- Trial name
- FLOW (NCT01069315)
- Testing
- Type of fluid lavage solution, Type of fluid lavage pressure
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 111 people
- Sponsor
- McMaster University
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Deafness, Hearing Loss
Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System)
The rationale behind this clinical performance investigation is to collect data regarding the usability of the Baha Attract System in patients with hearing impairment that are candidates for Baha surgery: To describe the expected…
- Conditions
- Deafness, Hearing Loss, Hearing Loss, Conductive
- Trial name
- NCT01822119
- Testing
- Baha Attract System
- Where
- 4 sites in Australia, Chile and 2 more
- Volunteers
- 27 people
- Sponsor
- Cochlear Bone Anchored Solutions
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Mydriasis
Evaluation of Pupil Dilation Speed With the MAP Dispenser
1 mist or 2 mists of the study drug will be administered to both eyes according to a pre-specified randomization plan to determine the effect on pupil dilation
- Trial name
- SPEED (NCT04907474)
- Testing
- tropicamide-phenylephrine fixed combination ophthalmic solution
- Where
- Mexico
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Eyenovia Inc.
Mycoses, Candidiasis
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
The purpose of this study is to assess the pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) of itraconazole (ITCZ) oral solution in participants…
- Conditions
- Mycoses, Candidiasis, Aspergillosis, Cryptococcosis
- Trial name
- NCT00784368
- Testing
- ITCZ Oral Solution, ITCZ-IV
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutical K.K.
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF3 (NCT00128492)
- Testing
- AZLI 75 mg two times a day (BID)/ three times a day (TID)
- Where
- 65 sites in United States, Australia and 2 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Contact Lens Care
Single Site Study of the Wettability of Contact Lenses With an Investigational Multi-Purpose Disinfecting Solution vs. a Marketed Multi-Purpose Solution
The purpose of this study is to clinically evaluate an investigational multi-purpose disinfecting solution (MPDS) compared to a commercial MPDS with respect to wettability of silicone hydrogel contact lenses.
- Trial name
- NCT00885092
- Testing
- FID 114675A Multi-Purpose Disinfecting Solution (MPDS), RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®), Senofilcon A contact lens (ACUVUE® Oasys™)
- Volunteers
- 40 people
- Sponsor
- Alcon Research
Hemodialysis Catheter Infection
Chlorhexidine Dressings for Hemodialysis Catheter Exit Site Care: Comparative Study
The objective of this study is to compare the rate of hemodialysis catheter-related infections according to the treatment regimen: chlorhexidine gluconate dressing or chlorhexidine solution.
- Trial name
- NCT05855616
- Testing
- Group "chlorhexidine dressing", Group "solution"
- Where
- Spain
- Volunteers
- 53 people
- Sponsor
- Hospital Universitario Marqués de Valdecilla
Hemophilia
A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions
The main aim is to describe how the treatment burden and challenges of participants, relatives, and doctors during regular Factor VIII and Factor IX infusions to treat hemophilia evolve using a virtual-reality (VR) based…
- Trial name
- NCT05437211
- Testing
- Virtual-reality (VR) Based Solution
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Takeda
Benign Pigmented Lesions, Facial Wrinkles
PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
Evaluation of the PicoWay™ Laser System With 730nm and Resolve™ Fusion Handpieces for Treatment of Benign Pigmented Lesions and Wrinkles.
- Trial name
- NCT03774849
- Testing
- PicoWay™ 532nm fractional handpiece, PicoWay™ 730nm wavelength, PicoWay™ 1064nm fractional handpiece
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Candela Corporation
Tinea Pedis
Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
The purpose of this study is to determine the fungicidal efficacy of nitric oxide releasing solution footbath and it's effect on the clinical signs and symptoms associated with Tinea Pedis
- Trial name
- NCT02871011
- Testing
- Nitric Oxide, Water
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nitric Solutions Inc.
Dermatosis Papulosa Nigra
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
- Trial name
- NCT03224598
- Testing
- A-101 Topical Solution 40%
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aclaris Therapeutics, Inc.
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in…
- Trial name
- NCT01215786
- Testing
- timolol ophthalmic solution 0.5%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allergan
Kidney Stone
Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis
Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in the non-Emergency Department…
- Trial name
- Flowmax (NCT00762424)
- Testing
- Flowmax
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- WellSpan Health
Rett Syndrome, RTT
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.
- Trial name
- NCT04252586
- Testing
- GWP42003-P
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.